Biotech Values

[turtlepower]

Re a lovenox authorized generic, the only instance that topic appeared to come up was at around the 28 minute mark. In response to an AG related question Viehbacher appeared to say that SNY doesn't want to tips its hand and then Spek said SNY would be ready when the right scenario occurs, whatever that scenario may be. I agree that he was probably referring to an additional generic entering the market. As long as m-enox maintains a 40-60% market share range there is no logic in introducing an AG.

http://www.thomson-webcast.net/uk/dispatching/?event_id=0c88d7ba71afe501d7b2e25c244be152&portal_id=2ba4dbdbaced91ffe0c73e301ff6ea0e